Genitourinary Cancer
News
Panel backs limited new olaparib use in prostate cancer
The ODAC panel voted 11 to 1 in favor of a restricted expansion.
Conference Coverage
Guidelines for assessing cancer risk may need updating
Whole-exome sequencing reveals cancer risk mutations in patients that would not have qualified for testing based on current guidelines.
News
Survival improved for some patients with metastatic cancers
Among patients with metastatic gastrointestinal stromal tumors, neuroendocrine tumors, melanoma, and several cancers, 5-year survival increased by...
News
Prostate cancer drug shortage leaves some with uncertainty
The therapy lutetium Lu 177 vipivotide tetraxetan will remain in limited supply until the drug’s manufacturer can ramp up production.
Commentary
COVID can mimic prostate cancer symptoms
“I had none of those previously reported experiences that could suddenly trigger a spike in PSA.”
News
Increased cancer in military pilots and ground crew: Pentagon
But military aircrew and ground crew were less likely to die from cancer, compared with the U.S. population.
Conference Coverage
Digital rectal exam fails as screening tool for prostate cancer
In a new study, 99% of digital rectal examinations did not raise suspicion for prostate cancer.
Conference Coverage
Urine test predicts future bladder cancer 12 years before symptoms
The test, if validated in further studies, has the potential to serve as a cancer screening tool for individuals at elevated risk for bladder...
Conference Coverage
Prostate cancer subgroup may benefit from intensified therapy
A new trial explored whether for patients with prostate cancer who have unfavorable features and a detectable PSA following a radical...
Conference Coverage
Talazoparib add-on improves outcomes in metastatic prostate cancer
As determined on the basis of imaging, PFS was 37% better for talazoparib plus enzalutamide than for enzalutamide monotherapy.